Disease Clusters?

Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.

← Back to all clusters

Cluster 17

22 diseases · 47 shared-gene connections
22 Diseases
67 Unique genes
0.191 Avg. similarity score
Epidermal nevus Most-connected disease (12 links)
Log in to save this analysis

Save This Analysis

Disease Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details · click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) · drag a node to pin it in place · scroll/pinch to zoom.

Member diseases (most connected first ‐ the cluster's core)

Disease ⇵ Connections in cluster ⇵ Significant partners ⇵ Curated genes ⇵
Epidermal nevus 12 12 7
Schimmelpenning-feuerstein-mims syndrome 11 11 3
Autoimmune lymphoproliferative disorder 8 8 11
Penile neoplasms 7 7 4
Bladder cancer 6 6 4
Nonmedullary thyroid cancer 5 5 7
Splenic neoplasms 5 5 1
Woolly hair nevus 5 5 1
Congenital arteriovenous malformation 4 4 9
Follicular thyroid cancer 4 4 7
Melanocytic nevus 4 4 11
Neurofibrosarcoma 4 4 1
Seminoma 4 4 3
Hypophosphatemic rickets 3 3 12
Splenomegaly 3 3 20
ciliary dyskinesia, primary, 39 3 3 1
Parkinson-dementia syndrome 1 1 1
autoimmune lymphoproliferative syndrome type 2A 1 1 1
bamforth-lazarus syndrome 1 1 1
immunodeficiency 64 1 1 1
lymphoproliferative syndrome 1 1 1 1
multisystemic smooth muscle dysfunction syndrome 1 1 1

Top shared genes (genes linked to 2+ member diseases)

Gene ⇵ Member diseases ⇵ Linked diseases
HRAS 12 / 22 Bladder cancer, Congenital arteriovenous malformation, Epidermal nevus, Follicular thyroid cancer and 8 more
NRAS 8 / 22 Autoimmune lymphoproliferative disorder, Epidermal nevus, Follicular thyroid cancer, Melanocytic nevus and 4 more
KRAS 6 / 22 Autoimmune lymphoproliferative disorder, Bladder cancer, Epidermal nevus, Penile neoplasms and 2 more
LRRC56 4 / 22 ciliary dyskinesia, primary, 39, Congenital arteriovenous malformation, Epidermal nevus, Hypophosphatemic rickets
FGFR3 3 / 22 Bladder cancer, Epidermal nevus, Seminoma
PIK3CA 3 / 22 Congenital arteriovenous malformation, Epidermal nevus, Penile neoplasms
ACTA2 2 / 22 Autoimmune lymphoproliferative disorder, multisystemic smooth muscle dysfunction syndrome
CASP10 2 / 22 Autoimmune lymphoproliferative disorder, autoimmune lymphoproliferative syndrome type 2A
CASP8 2 / 22 Autoimmune lymphoproliferative disorder, Melanocytic nevus
FAS 2 / 22 Autoimmune lymphoproliferative disorder, Splenomegaly
FOXE1 2 / 22 bamforth-lazarus syndrome, Nonmedullary thyroid cancer
ITK 2 / 22 Autoimmune lymphoproliferative disorder, lymphoproliferative syndrome 1
MAPT 2 / 22 Parkinson-dementia syndrome, Splenomegaly
MINPP1 2 / 22 Follicular thyroid cancer, Nonmedullary thyroid cancer
RASGRP1 2 / 22 Autoimmune lymphoproliferative disorder, immunodeficiency 64
SRGAP1 2 / 22 Follicular thyroid cancer, Nonmedullary thyroid cancer
TP53 2 / 22 Melanocytic nevus, Penile neoplasms
What do these columns mean?
Connections in cluster
How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
Significant partners
How many of those links are statistically significant (FDR q < 0.05).
Curated genes
Distinct curated genes linked to that disease in GeDiPNet.
Member diseases (Top shared genes)
How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
Overlap genes (x / y)
x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
Cluster gene count
Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
Fold enrichment
Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
P-value / FDR q-value
Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
Shared genes (Pairs within this cluster)
Number of curated genes the two diseases in that row have in common.
Similarity score (Pairs within this cluster)
Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.

Enriched Pathways (why this cluster is grouped, biologically)

Pathway ⇵ Source ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
Pathways in cancer
CASP8, FAS, FASLG, NRAS, RASGRP1, KRAS, FGF23, FGFR3, HRAS, RB1, GLI2, MAP2K1
 KEGG 23 / 533 7.7× 4.12e-15 1.42e-12 ✓ sig.
Hepatitis C
CASP8, FAS, FASLG, NRAS, KRAS, HRAS, RB1, MAP2K1, PIK3CA, TP53, EIF2AK1, OCLN
 KEGG 12 / 159 13.5× 6.11e-11 9.19e-9 ✓ sig.
MAPK signaling pathway
FAS, FASLG, NRAS, RASGRP1, KRAS, FGF23, FGFR3, HRAS, CACNA1H, MAP2K1, TEK, TP53
 KEGG 15 / 299 9.0× 6.65e-11 9.92e-9 ✓ sig.
Hepatitis B
CASP10, CASP8, FAS, FASLG, NRAS, KRAS, HRAS, RB1, MAP2K1, PIK3CA, TP53, STAT5B
 KEGG 12 / 163 13.2× 8.18e-11 1.20e-8 ✓ sig.
Apoptosis
CASP10, CASP8, FAS, FASLG, NRAS, KRAS, HRAS, MAP2K1, PIK3CA, ATM, TP53
 KEGG 11 / 137 14.4× 2.12e-10 2.83e-8 ✓ sig.
Chronic myeloid leukemia
NRAS, KRAS, HRAS, RB1, MAP2K1, PIK3CA, TP53, MECOM, STAT5B
 KEGG 9 / 77 21.0× 3.59e-10 4.55e-8 ✓ sig.
Thyroid cancer
NRAS, KRAS, HRAS, MAP2K1, TP53, PAX8, PPARG
 KEGG 7 / 37 33.9× 1.10e-9 1.23e-7 ✓ sig.
Signaling by FGFR3 fusions in cancer
NRAS, KRAS, FGFR3, HRAS, PIK3CA
 Reactome 5 / 10 89.6× 1.14e-9 1.26e-7 ✓ sig.
Signaling by FGFR3 point mutants in cancer
NRAS, KRAS, FGF23, FGFR3, HRAS, PIK3CA
 Reactome 6 / 22 48.9× 1.67e-9 1.75e-7 ✓ sig.
Bladder cancer
NRAS, KRAS, FGFR3, HRAS, RB1, MAP2K1, TP53
 KEGG 7 / 41 30.6× 2.36e-9 2.39e-7 ✓ sig.
Human papillomavirus infection
CASP8, FAS, FASLG, NRAS, KRAS, HRAS, RB1, MAP2K1, PIK3CA, ATM, TP53, APC
 KEGG 14 / 333 7.5× 3.14e-9 3.11e-7 ✓ sig.
Activation of RAS in B cells
NRAS, RASGRP1, KRAS, HRAS
 Reactome 4 / 5 143× 4.40e-9 4.24e-7 ✓ sig.
FasL/ CD95L signaling
CASP10, CASP8, FAS, FASLG
 Reactome 4 / 5 143× 4.40e-9 4.24e-7 ✓ sig.
Central carbon metabolism in cancer
NRAS, KRAS, FGFR3, HRAS, MAP2K1, PIK3CA, TP53, FLT3
 KEGG 8 / 71 20.2× 4.92e-9 4.67e-7 ✓ sig.
Ras signaling pathway
FASLG, NRAS, RASGRP1, KRAS, FGF23, FGFR3, HRAS, MAP2K1, PIK3CA, TEK, PLA2G6, FLT3
 KEGG 12 / 237 9.1× 6.07e-9 5.67e-7 ✓ sig.

Enriched GO Terms (Biological Process, a second line of biological evidence)

GO term ⇵ GO ID ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
positive regulation of gene expression
ACTA2, KRAS, HRAS, MAP2K1, VDR, ATM, TP53, APP, NFE2L2, NOTCH1, OCLN, PSEN1
 GO:0010628 14 / 504 7.7× 2.38e-9 4.81e-7 ✓ sig.
negative regulation of gene expression
HRAS, RB1, MAP2K1, PIK3CA, TP53, MAPT, APOE, APP, NOTCH1, OCLN, PSEN1, PPARG
 GO:0010629 12 / 339 9.9× 2.57e-9 5.14e-7 ✓ sig.
intracellular phosphate ion homeostasis
FGF23, SLC34A3, ENPP1, SLC34A1
 GO:0030643 4 / 10 112× 3.12e-8 4.54e-6 ✓ sig.
positive regulation of ERK1 and ERK2 cascade
ACTA2, FGF23, FGFR3, HRAS, MAP2K1, TEK, APOE, APP, NOTCH1
 GO:0070374 9 / 201 12.5× 4.02e-8 5.63e-6 ✓ sig.
thyroid gland development
MAP2K1, CGA, PAX8, NKX2-1, FOXE1
 GO:0030878 5 / 30 46.5× 6.77e-8 8.74e-6 ✓ sig.
positive regulation of neuron apoptotic process
CASP10, CASP8, FASLG, ATM, TP53, APP
 GO:0043525 6 / 65 25.7× 1.18e-7 1.39e-5 ✓ sig.
positive regulation of apoptotic process
CASP8, FAS, FASLG, CTLA4, ATM, TP53, APC, APP, NOTCH1, PSEN1
 GO:0043065 10 / 326 8.6× 2.34e-7 2.47e-5 ✓ sig.
Ras protein signal transduction
NRAS, RASGRP1, KRAS, HRAS, RB1, TP53
 GO:0007265 6 / 79 21.2× 3.83e-7 3.73e-5 ✓ sig.
positive regulation of amyloid fibril formation
APOE, APP, PSEN1
 GO:1905908 3 / 5 167× 4.38e-7 4.18e-5 ✓ sig.
positive regulation of DNA-templated transcription
FGF23, GLI2, MAP2K1, TP53, AHR, APOE, MECOM, NFE2L2, NOTCH1, PSEN1, PAX8, PPARG
 GO:0045893 14 / 778 5.0× 5.26e-7 4.87e-5 ✓ sig.
positive regulation of transcription by RNA polymerase II
HRAS, RB1, GLI2, VDR, ATM, MAFF, TP53, AHR, APP, MECOM, NFE2L2, NOTCH1
 GO:0045944 17 / 1,208 3.9× 8.27e-7 7.10e-5 ✓ sig.
thymus development
MAP2K1, ATM, TYR, PSEN1, FOXE1
 GO:0048538 5 / 50 27.9× 9.52e-7 7.98e-5 ✓ sig.
neuron apoptotic process
KRAS, HRAS, RB1, ATM, TP53, PSEN1
 GO:0051402 6 / 98 17.1× 1.37e-6 1.07e-4 ✓ sig.
cellular senescence
PRKCD, HRAS, MAP2K1, ATM, TP53
 GO:0090398 5 / 57 24.5× 1.85e-6 1.35e-4 ✓ sig.
apoptotic process
CASP10, CASP8, FAS, FASLG, PRKCD, FGFR3, RB1, TP53, AHR, APP, MECOM, NOTCH1
 GO:0006915 13 / 747 4.9× 2.07e-6 1.48e-4 ✓ sig.

Pairs within this cluster, by significance

Disease A ⇵ Disease B ⇵ Similarity score ⇵ Shared genes ⇵ P-value ⇵ FDR q-value ⇵
Follicular thyroid cancer Nonmedullary thyroid cancer 0.364 4 5.23e-13 6.86e-12 ✓ sig.
Epidermal nevus Schimmelpenning-feuerstein-mims syndrome 0.375 3 5.75e-11 6.20e-10 ✓ sig.
Epidermal nevus Penile neoplasms 0.333 3 2.30e-10 2.34e-9 ✓ sig.
Bladder cancer Epidermal nevus 0.333 3 2.30e-10 2.34e-9 ✓ sig.
Congenital arteriovenous malformation Epidermal nevus 0.214 3 4.83e-9 4.31e-8 ✓ sig.
Bladder cancer Schimmelpenning-feuerstein-mims syndrome 0.333 2 1.52e-7 1.09e-6 ✓ sig.
Bladder cancer Seminoma 0.333 2 1.52e-7 1.09e-6 ✓ sig.
Penile neoplasms Schimmelpenning-feuerstein-mims syndrome 0.333 2 1.52e-7 1.09e-6 ✓ sig.
Bladder cancer Penile neoplasms 0.286 2 3.04e-7 2.06e-6 ✓ sig.
Autoimmune lymphoproliferative disorder Splenomegaly 0.103 3 3.07e-7 2.08e-6 ✓ sig.
Follicular thyroid cancer Schimmelpenning-feuerstein-mims syndrome 0.222 2 5.31e-7 3.46e-6 ✓ sig.
Nonmedullary thyroid cancer Schimmelpenning-feuerstein-mims syndrome 0.222 2 5.31e-7 3.46e-6 ✓ sig.
Epidermal nevus Seminoma 0.222 2 5.31e-7 3.46e-6 ✓ sig.
Melanocytic nevus Schimmelpenning-feuerstein-mims syndrome 0.154 2 1.39e-6 8.41e-6 ✓ sig.
Autoimmune lymphoproliferative disorder Schimmelpenning-feuerstein-mims syndrome 0.154 2 1.39e-6 8.41e-6 ✓ sig.
Congenital arteriovenous malformation Penile neoplasms 0.167 2 1.82e-6 1.08e-5 ✓ sig.
Melanocytic nevus Penile neoplasms 0.143 2 2.78e-6 1.59e-5 ✓ sig.
Epidermal nevus Nonmedullary thyroid cancer 0.154 2 3.72e-6 2.09e-5 ✓ sig.
Epidermal nevus Follicular thyroid cancer 0.154 2 3.72e-6 2.09e-5 ✓ sig.
Schimmelpenning-feuerstein-mims syndrome Splenomegaly 0.091 2 4.80e-6 2.64e-5 ✓ sig.
Epidermal nevus Melanocytic nevus 0.118 2 9.72e-6 5.10e-5 ✓ sig.
Autoimmune lymphoproliferative disorder Epidermal nevus 0.118 2 9.72e-6 5.10e-5 ✓ sig.
Epidermal nevus Hypophosphatemic rickets 0.111 2 1.17e-5 6.04e-5 ✓ sig.
Congenital arteriovenous malformation Hypophosphatemic rickets 0.100 2 2.00e-5 1.00e-4 ✓ sig.
Autoimmune lymphoproliferative disorder Melanocytic nevus 0.095 2 2.54e-5 1.25e-4 ✓ sig.
Splenic neoplasms Woolly hair nevus 0.500 1 6.49e-5 2.34e-4 ✓ sig.
Seminoma Splenic neoplasms 0.250 1 1.95e-4 5.28e-4 ✓ sig.
Seminoma Woolly hair nevus 0.250 1 1.95e-4 5.28e-4 ✓ sig.
Neurofibrosarcoma Schimmelpenning-feuerstein-mims syndrome 0.250 1 1.95e-4 5.28e-4 ✓ sig.
Schimmelpenning-feuerstein-mims syndrome Splenic neoplasms 0.250 1 1.95e-4 5.28e-4 ✓ sig.
Schimmelpenning-feuerstein-mims syndrome Woolly hair nevus 0.250 1 1.95e-4 5.28e-4 ✓ sig.
Penile neoplasms Woolly hair nevus 0.200 1 2.60e-4 6.40e-4 ✓ sig.
Penile neoplasms Splenic neoplasms 0.200 1 2.60e-4 6.40e-4 ✓ sig.
Bladder cancer Splenic neoplasms 0.200 1 2.60e-4 6.40e-4 ✓ sig.
Bladder cancer Woolly hair nevus 0.200 1 2.60e-4 6.40e-4 ✓ sig.
bamforth-lazarus syndrome Nonmedullary thyroid cancer 0.125 1 4.55e-4 9.55e-4 ✓ sig.
ciliary dyskinesia, primary, 39 Epidermal nevus 0.125 1 4.55e-4 9.55e-4 ✓ sig.
Neurofibrosarcoma Nonmedullary thyroid cancer 0.125 1 4.55e-4 9.55e-4 ✓ sig.
Epidermal nevus Neurofibrosarcoma 0.125 1 4.55e-4 9.55e-4 ✓ sig.
Follicular thyroid cancer Neurofibrosarcoma 0.125 1 4.55e-4 9.55e-4 ✓ sig.
ciliary dyskinesia, primary, 39 Congenital arteriovenous malformation 0.100 1 5.84e-4 1.14e-3 ✓ sig.
Autoimmune lymphoproliferative disorder lymphoproliferative syndrome 1 0.083 1 7.14e-4 1.31e-3 ✓ sig.
Autoimmune lymphoproliferative disorder autoimmune lymphoproliferative syndrome type 2A 0.083 1 7.14e-4 1.31e-3 ✓ sig.
Autoimmune lymphoproliferative disorder multisystemic smooth muscle dysfunction syndrome 0.083 1 7.14e-4 1.31e-3 ✓ sig.
Autoimmune lymphoproliferative disorder immunodeficiency 64 0.083 1 7.14e-4 1.31e-3 ✓ sig.
ciliary dyskinesia, primary, 39 Hypophosphatemic rickets 0.077 1 7.79e-4 1.39e-3 ✓ sig.
Parkinson-dementia syndrome Splenomegaly 0.048 1 1.30e-3 2.04e-3 ✓ sig.